IL-1β-mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes

Journal of Immunology

Volumn 174, Issue 8, 2005, Pages 4991-4997

  O'Connor, Jason C ^a   Satpathy, Ansuman ^a   Hartman, Matthew E ^a   Horvath, Emily M ^a   Kelley, Keith W ^a   Dantzer, Robert ^b   Johnson, Rodney W ^a   Freund, Gregory G ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; DNA; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; MESSENGER RNA; RECOMBINANT PROTEIN; SIALOGLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE AMPLIFICATION; INNATE IMMUNITY; MACROPHAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BRAIN; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PERITONEUM MACROPHAGE;

ANIMALS; BASE SEQUENCE; BRAIN; DIABETES MELLITUS, TYPE 2; DNA; IMMUNITY, NATURAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, IMMUNOLOGICAL; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II; RECOMBINANT PROTEINS; RNA, MESSENGER; SIALOGLYCOPROTEINS;

EID: 17044425940     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.8.4991     Document Type: Article

References (49)

1. Pradhan, A. D., J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J. Am. Med. Assoc. 286:327.
2. Barzilay, J. I., L. Abraham, S. R. Heckbert, M. Cushman, L. H. Kuller, H. E. Resnick, and R. P. Tracy. 2001. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384.
3. Festa, A., R. D'Agostino, Jr., R. P. Tracy, and S. M. Haffner. 2002. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131.
4. Spranger, J., A. Kroke, M. Mohlig, K. Hoffmann, M. M. Bergmann, M. Ristow, H. Boeing, and A. F. Pfeiffer. 2003. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812.
5. Pickup, J. C., G. D. Chusney, S. M. Thomas, and D. Burt. 2000. Plasma interteukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci. 67:291.
6. Nguyen, M. D., T. D'Aigle, G. Gowing, J. P. Julien, and S. Rivest. 2004. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 24:1340.
7. Cesari, M., B. W. Penninx, A. B. Newman, S. B. Kritchevsky, B. J. Nicklas, K. Sutton-Tyrrell, S. M. Rubin, J. Ding, E. M. Simonsick, T. B. Harris, and M. Pahor. 2003. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108:2317.
8. Yaffe, K., K. Lindquist, B. W. Penninx, E. M. Simonsick, M. Pahor, S. Kritchevsky, L. Launer, L. Kuller, S. Rubin, and T. Harris. 2003. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61:76.
9. Penninx, B. W., S. B. Kritchevsky, K. Yaffe, A. B. Newman, E. M. Simonsick, S. Rubin, L. Ferrucci, T. Harris, and M. Pahor. 2003. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry 54:566.
10. Sluzewska, A., J. Rybakowski, E. Bosmans, M. Sobieska, R. Berghmans, M. Maes, and K. Wiktorowicz. 1996. Indicators of immune activation in major depression. Psychiatry Res. 64:161.
11. Cavaillon, J. M. 2001. Pro- versus anti-inflammatory cytokines: myth or reality. Cell Mol. Biol. 47:695.
12. Rupp, J., H. Kothe, A. Mueller, M. Maass, and K. Dalhoff. 2003. Imbalanced secretion of IL-1β and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur. Respir. J. 22:274.
13. Shah, B. R., and J. E. Hux. 2003. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26:510.
14. Kent, S., J. L. Bret-Dibat, K. W. Kelley, and R. Dantzer. 1996. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci. Biobehav. Rev. 20:171.
15. Hart, B. L. 1988. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 12:123.
16. Johnson, R. W., G. Gheusi, S. Segreti, R. Dantzer, and K. W. Kelley. 1997. C3H/HeJ mice are refractory to lipopolysaccharide in the brain. Brain Res. 752:219.
17. Segreti, J., G. Gheusi, R. Dantzer, K. W. Kelley, and R. W. Johnson. 1997. Defect in interleukin-1β secretion prevents sickness behavior in C3H/HeJ mice. Physiol. Behav. 61:873.
18. Swiergiel, A. H., G. N. Smagin, and A. J. Dunn. 1997. Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacol. Biochem. Behav. 57:389.
19. Konsman, J. P., K. Kelley, and R. Dantzer. 1999. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1β and inducible nitric oxide synthase in rat brain. Neuroscience 89:535.
20. Burgess, W., G. Gheusi, J. Yao, R. W. Johnson, R. Dantzer, and K. W. Kelley. 1998. Interleukin-1β-converting enzyme-deficient mice resist central but not systemic endotoxin-induced anorexia. Am. J. Physiol. 274:R1829.
21. Sonti, G., M. C. Flynn, and C. R. Plata-Salaman. 1997. Interleukin-1 (IL-1) receptor type 1 mediates anorexia but not adipsia induced by centrally administered IL-1β. Physiol. Behav. 62:1179.
22. Bluthe, R. M., S. Laye, B. Michaud, C. Combe, R. Dantzer, and P. Parnet. 2000. Role of interleukin-1β and tumour necrosis factor-α in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur. J. Neurosci. 12:4447.
23. Acton, R. D., P. S. Dahlberg, M. E. Uknis, H. G. Klaerner, G. S. Fink, J. G. Norman, and D. L. Dunn. 1996. Differential sensitivity to Escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors. Arch Surg. 131:1216.
24. Dinarello, C. A. 2000. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343:732.
25. McMahan, C. J., J. L. Slack, B. Mosley, D. Cosman, S. D. Lupton, L. L. Brunton, C. E. Grubin, J. M. Wignall, N. A. Jenkins, C. I. Brannan, et al. 1991. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10:2821.
26. Dantzer, R. 2001. Cytokine-induced sickness behavior: where do we stand? Brain Behav. Immun. 15:7.
27. Licinio, J., and M. L. Wong. 1997. Interleukin 1 receptor antagonist gene expression in rat pituitary in the systemic inflammatory response syndrome: pathophysiological implications. Mol. Psychiatry 2:99.
28. Hirsch, E., V. M. Irikura, S. M. Paul, and D. Hirsh. 1996. Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Natl. Acad. Sci. USA 93:11008.
29. Bluthe, R. M., C. Beaudu, K. W. Kelley, and R. Dantzer. 1995. Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res. 677:171.
30. Cartmell, T., G. N. Luheshi, S. J. Hopkins, N. J. Rothwell, and S. Poole. 2001. Role of endogenous interleukin-1 receptor antagonist in regulating fever induced by localised inflammation in the rat. J. Physiol. 531:171.
31. Cremona, S., S. Laye, R. Dantzer, and P. Parnet. 1998. Blockade of brain type II interleukin-1 receptors potentiates IL1β-induced anorexia in mice. Neurosci. Lett. 246:101.
32. Hartman, M. E., J. C. O'Connor, J. P. Godbout, K. D. Minor, V. R. Mazzocco, and G. G. Freund. 2004. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. J. Biol. Chem. 279:28045.
33. -ΔΔT method. Methods 25:402.
34. Ceddia, M. A., and J. A. Woods. 1999. Exercise suppresses macrophage antigen presentation. J. Appl. Physiol. 87:2253.
35. Bluthe, R. M., B. Michaud, K. W. Kelley, and R. Dantzer. 1996. Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. Neuroreport 7:1485.
36. Dantzer, R. 2001. Cytokine-induced sickness behavior: mechanisms and implications. Ann. NY Acad. Sci. 933:222.
37. Bluthe, R. M., V. Walter, P. Parnet, S. Laye, J. Lestage, D. Verrier, S. Poole, B. E. Stenning, K. W. Kelley, and R. Dantzer. 1994. Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C. R. Acad. Sci. Ser. III 317:499.
38. Fahey, T. J., III, A. Sadaty, W. G. Jones II, A. Barber, B. Smoller, and G. T. Shires. 1991. Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50:308.
39. Bluthe, M. Jafarian-Tehrani, B. Michaud, F. Haour, R. Dantzer, and F. Homo-Delarche. 1999. Increased sensitivity of prediabetic nonobese diabetic mouse to the behavioral effects of IL-1. Brain Behav. Immun. 13:303.
40. Plata-Salaman, C. R., E. Peloso, and E. Satinoff. 1998. Cytokine-induced fever in obese (fa/fa) and lean (Fa/Fd) Zucker rats. Am. J. Physiol 275:R1353.
41. Romanovsky, A. A., A. I. Ivanov, M. J. Lenczowski, V. A. Kulchitsky, A. M. Van Dam, S. Poole, L. D. Homer, and F. J. Tilders. 2000. Lipopolysaccharide transport from the peritoneal cavity to the blood: is it controlled by the vagus nerve? Auton. Neurosci. 85:133.
42. Yokochi, T., Y. Inoue, J. Yokoo, Y. Kimura, and N. Kato. 1989. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect. Immun. 57:1786.
43. Naguib, G., H. Al-Mashat, T. Desta, and D. T. Graves. 2004. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J. Invest. Dermatol. 123:87.
44. O'Rourke, L., L. M. Gronning, S. J. Yeaman, and P. R. Shepherd. 2002. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J. Biol. Chem. 277:42557.
45. Iida, K. T., H. Shimano, Y. Kawakami, H. Sone, H. Toyoshima, S. Suzuki, T. Asano, Y. Okuda, and N. Yamada. 2001. Insulin up-regulates tumor necrosis factor-α production in macrophages through an extracellular-regulated kinase-dependem pathway. J. Biol. Chem. 276:32531.
46. Stoffels, K., L. Overbergh, A. Giulietti, A. Kasran, R. Bouillon, C. Gysemans, and C. Mathieu. 2004. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J. Autoimmun. 23:9.
47. Wang, J. Y., J. M. Yang, P. L. Tao, and S. N. Yang. 2001. Synergistic apoptosis induced by bacterial endotoxin lipopolysaccharide and high glucose in rat microglia. Neurosci. Lett. 304:177.
48. Zykova, S. N., T. G. Jenssen, M. Berdal, R. Olsen, R. Myklebust, and R. Seljelid. 2000. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/dh mice. Diabetes 49:1451.
49. Cohen, S. B. 2004. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 30:365.